focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,774.50
Ask: 1,775.50
Change: 0.00 (0.00%)
Spread: 1.00 (0.056%)
Open: 1,775.50
High: 1,778.50
Low: 1,769.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-SSE says no break-up decision after report of Elliott pressure

Mon, 20th Sep 2021 08:33

* SSE backs current strategy

* Shares closed higher on Monday

* The Telegraph reported company was close to splitting

* Source says Elliott is among top 5 shareholders in SSE
(Adds background, context, chart, updates shares)

By Muvija M

Sept 20 (Reuters) - Britain's SSE has not made a
decision to split itself up, the renewable power and networks
group said on Monday in response to a newspaper report that it
was close to doing so after months of pressure from U.S.
activist investor Elliott.

A source close to the situation confirmed that Elliott was
one of the top five investors in the blue-chip company, holding
a stake just under the 5% threshold that would require formal
disclosure.

SSE, which declined to comment on Elliott's reported
involvement or stakeholding, said it would update investors on
growth plans in due course. It is scheduled to report interim
results in mid-November.

SSE shares have gained nearly 9% this year, with more than
6% of the rise having come after a media report in early August
about Elliott buying a stake. The company has a market valuation
of more than 17 billion pounds ($23.2 billion).

SSE has been sharpening its focus on renewable power
generation and electricity networks after the sale of its retail
division to OVO Energy. It plans to invest 7.5 billion pounds
($10.3 billion) in low-carbon projects up to 2025.

By splitting SSE's renewables business from networks the
company could attract a couple of billion pounds from investors
who are ESG-focussed, the source said.

The source added that conversations between Elliott and SSE
are understood to have been constructive.

On Monday the stock closed 0.4% higher, outshining the main
bourse that ended down 0.8%.

SSE's statement followed a Telegraph report on Friday https://bit.ly/3lE1yQe
that the company was close to splitting into two separate
blue-chip companies.

"The Board remains fully focused on strategic choices which
will drive shareholder value from the wealth of net zero
opportunities the company is creating," SSE said.

"SSE is currently building more offshore wind than any
company in the world, expanding internationally, and investing
in the low-carbon electricity infrastructure."

New York-based Elliott, which in the past had pushed for
changes at Premier-Inn owner Whitbread, has more
recently targeted London-listed pharmaceutical giant GSK
.

The hedge fund has been in talks with SSE's board to
separate the company's wholesale networks business from its
renewables operations for more than a year, the Telegraph report
added, citing unidentified sources.

Elliott declined a Reuters request for comment on the
report.

Energy companies in Britain and across the world are under
the spotlight amid a surge in gas prices.
($1 = 0.7313 pounds)

(Reporting by Chris Peters and Muvija M in Bengaluru
Editing by Saumyadeb Chakrabarty, Mark Potter and Keith Weir)

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.